Business
OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
MISSOULA, Mont., February 03, 2026--OSRX remains licensed and operational in California, continuing uninterrupted access to compounded ophthalmic medications.
About this update from Harrow, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/a160a15d305b8f68b6f7a63b69b5bf14"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/F.L_L.H8Fwvife9vpTtAqw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a160a15d305b8f68b6f7a63b69b5bf14","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/McF0cuW59X2Y8IkVWeKDag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a160a15d305b8f68b6f7a63b69b5bf14","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/sxl6pBl.dpcCf2BLpcYpnQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/a160a15d305b8f68b6f7a63b69b5bf14","width":1024,"height":512}},"lazy":false},{"type":"text","content":"The Montana-based compounder commits to supporting prescribers and patients in wake of competitor’s abrupt exit of California market","length":132,"tagName":"p","attribs":{}},{"type":"text","content":"MISSOULA, Mont., February 03, 2026--(BUSINESS WIRE)--OSRX, Inc., a leading provider of compounded ophthalmic medications, announced that the company remains fully licensed, fully operational and continues to serve the needs of California ophthalmologists and optometrists, following a significant market shift involving a major competitor.","length":339,"tagName":"p"},{"type":"text","content":"According to a Feb. 2, 2026 company disclosure, ImprimisRx – the compounding division of Harrow (NASDAQ:HROW) – voluntarily forfeited its California license on February 1 and agreed to pay an administrative fine of approximately $157,000 as part of a settlement agreement reached with the California Board of Pharmacy (CBOP).1 The CBOP previously filed a formal accusation against ImprimisRx in August 2025 outlining multiple causes for discipline.2","length":449,"tagName":"p"},{"type":"text","content":"This licensing action pertains solely to ImprimisRx and does not affect other 503B outsourcing facilities in good standing with the California Board of Pharmacy, including OSRX.","length":177,"tagName":"p"},{"type":"text","content":"With many prescribers utilizing compounded ophthalmic medic...